gammaCore Sapphire

DEVICE4 trials

Sponsors

University of Toledo Health Science Campus, University of Texas Southwestern Medical Center, Leiden University Medical Center, National Taiwan University Hospital

Conditions

AnxietyCerebral Amyloid AngiopathyDepressionNeuromodulationPost-Traumatic HeadachePrimary Raynaud PhenomenonRaynaud DiseaseRaynaud Phenomenon

Phase 2

Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy

Enrolling by invitationNCT06421532

Leiden University Medical CenterCerebral Amyloid Angiopathy

Start: 2025-03-27End: 2027-09-27Target: 60Updated: 2026-02-24

Unknown Phase

Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.

TerminatedNCT03869008

University of Toledo Health Science CampusPrimary Raynaud Phenomenon, Raynaud Disease, Raynaud Phenomenon +1

Start: 2019-04-30End: 2020-02-27Updated: 2025-07-15

Study of Gammacore Sapphire for the Acute and Preventive Treatment of Post-Traumatic Headache (GAP-PTH)

WithdrawnNCT04071743

University of Texas Southwestern Medical CenterPost-Traumatic Headache

Start: 2020-01-01End: 2021-12-31Updated: 2020-03-10

Treatment of SSD With tcVNS and taVNS

Enrolling by invitationNCT07198542

National Taiwan University HospitalAnxiety, Depression, Neuromodulation +2

Start: 2025-11-17End: 2028-12-31Target: 60Updated: 2025-12-12

Related Papers

Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial.

2026-03-11